Wu H, Li C, Li H, Shang L, Jing HY, Liu J, Fang Z, Du FY, Liu Y, Fu MD, Jiang KW, Li LP. Clinicopathological characteristics and longterm survival of patients with synchronous multiple primary gastrointestinal stromal tumors: A propensity score matching analysis. World J Gastroenterol 2021; 27(36): 6128-6141 [PMID: 34629824 DOI: 10.3748/wjg.v27.i36.6128]
Corresponding Author of This Article
Le-Ping Li, MD, Full Professor, Department of Gastroenterological Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, No. 324 Jingwuweiqi road, Huaiyin District, Jinan 250021, Shandong Province, China. lileping@sdu.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Sep 28, 2021; 27(36): 6128-6141 Published online Sep 28, 2021. doi: 10.3748/wjg.v27.i36.6128
Table 1 Preoperative clinical characteristics of solitary gastrointestinal stromal tumors and multiple gastrointestinal stromal tumors in the entire cohort and after propensity score matching
Table 2 Surgical and postoperative pathological characteristics and treatment of the solitary gastrointestinal stromal tumors and multiple gastrointestinal stromal tumors of the entire cohort and after propensity score matching
Parameters
Entire cohort, before matching
P value
Propensity score matched cohort
P value
SGIST, n (%)
MGIST, n (%)
SGIST, n (%)
MGIST, n (%)
All cases
942
41
164
41
Surgical approach
0.028
0.361
Open
458 (48.62)
27 (65.85)
94 (57.32)
27 (65.85)
Laparoscopic
255 (27.07)
11 (26.83)
43 (26.22)
11 (26.83)
Endoscopic
229 (24.31)
3 (7.32)
27 (14.63)
3 (7.32)
Blood transfusion
0.161
1.000
Yes
171 (18.15)
11 (26.83)
44 (26.83)
11 (26.83)
No
771 (81.85)
30 (73.17)
120 (73.17)
30 (73.17)
Tumor size (cm)
0.007
0.200
Length ≤ 5
575 (61.04)
15 (36.59)
74 (45.12)
15 (36.59)
5 < Length ≤ 10
239 (25.37)
16 (39.02)
41 (25.00)
16 (39.02)
Length > 10
128 (13.59)
10 (24.39)
49 (29.88)
10 (24.39)
Mitotic index (per 50 HPF)
0.009
0.715
0-5
724 (76.86)
27 (65.85)
101 (61.59)
27 (65.85)
6-10
127 (13.48)
4 (9.76)
24 (14.63)
4 (9.76)
> 10
91 (9.66)
10 (24.39)
39 (23.78)
10 (24.39)
Modified NIH risk
0.044
0.486
Very low
210 (22.29)
4 (9.76)
29 (17.68)
4 (9.76)
Low
291 (30.89)
9 (21.95)
30 (18.29)
9 (21.95)
Intermediate
147 (15.61)
8 (19.51)
22 (13.41)
8 (19.51)
High
294 (31.21)
20 (48.78)
83 (50.61)
20 (48.78)
Operate time (min)
0.336
0.627
mean ± SD
139 ± 78
151 ± 63
145 ± 67
151 ± 63
Median (IQR)
120 (80-180)
150 (120-180)
140 (90-190)
150 (120-180)
Intraoperative tumor rupture
0.376
0.490
Yes
10 (1.06)
1 (2.44)
2 (1.22)
1 (2.44)
No
932 (98.94)
40 (97.56)
162 (98.78)
40 (97.56)
Hospitalization time in d
0.226
0.442
mean ± SD
13.55 ± 6.32
14.78 ± 7.66
13.96 ± 5.69
14.78 ± 7.66
Median (IQR)
12 (10-15)
14 (9-16)
13 (11-16)
14 (9-16)
Postoperative complications
0.391
0.610
Present
179 (19.00)
10 (24.39)
34 (20.73)
10 (24.39)
Absent
763 (81.00)
31 (73.61)
130 (79.27)
31 (73.61)
Imatinib treatment
0.187
0.832
Yes
298 (31.63)
17 (41.46)
71 (43.29)
17 (41.46)
No
644 (68.37)
24 (58.54)
93 (56.71)
24 (58.54)
Table 3 Univariate and multivariate of the clinicopathological factors for progression-free survival
Characteristics
Univariate analysis
Multivariate analysis
HR (95%CI)
P value
HR (95%CI)
P value
Age in yr
≤ 60
Reference
Reference
> 60
1.845 (0.953-3.571)
0.069
1.525 (0.740-3.143)
0.252
Sex
Female
Reference
Male
0.913 (0.460-1.809)
0.793
Comorbidities
Absent
Reference
Present
1.147 (0.606-2.172)
0.673
Tumor location
Gastric
Reference
Reference
Non-gastric
3.548 (1.847-6.818)
< 0.001
3.176 (1.526-6.607)
0.002
Tumor size in cm
0.001
0.035
Length ≤ 5
Reference
Reference
5 < Length ≤ 10
3.022 (1.117-8.179)
0.029
2.180 (0.716-6.642)
0.170
Length > 10
5.848 (2.359-14.499)
< 0.001
4.071 (1.375-12.052)
0.011
Mitotic index, per 50 HPF
< 0.001
0.001
0-5
Reference
Reference
6-10
4.094 (1.555-10.777)
0.004
4.108 (1.309-12.897)
0.015
> 10
7.859 (3.676-16.799)
< 0.001
6.577 (2.540-17.029)
< 0.001
Surgical approach
0.251
Open
Reference
Laparoscopic
0.449 (0.174-1.154)
0.096
Endoscopic
0 (0-1.006E+230)
0.961
Blood transfusion
No
Reference
Reference
Yes
2.176 (1.143-4.145)
0.018
1.569 (0.739-3.332)
0.241
Intraoperative tumor rupture
No
Reference
Reference
Yes
6.383 (1.524-26.726)
0.011
4.458 (0.863-23.015)
0.074
Imatinib treatment
Yes
Reference
Reference
No
0.584 (0.290-1.178)
0.133
4.608 (2.030-10.461)
< 0.001
MGIST
Absent
Reference
Reference
Present
2.091 (1.055-4.145)
0.035
2.431 (1.097-5.386)
0.029
Table 4 Univariate and multivariate analysis of the clinicopathological factors for overall survival
Characteristics
Univariate analysis
Multivariate analysis
HR (95%CI)
P value
HR (95%CI)
P value
Age in yr
≤ 65
Reference
> 65
1.665 (0.754-3.676)
0.207
Gender
Female
Reference
Male
1.099 (0.461-2.616)
0.832
Comorbidities
Absent
Reference
Present
1.061 (0.491-2.291)
0.881
Tumor location
Gastric
Reference
Reference
Non-gastric
4.428 (1.967-9.965)
< 0.001
3.812 (1.577-9.213)
0.003
Tumor size in cm
0.021
0.556
Length ≤ 5
Reference
Reference
5 < Length ≤ 10
2.279 (0.722-7.189)
0.160
1.381 (0.346-5.519)
0.648
Length > 10
4.159 (1.498-11.549)
0.006
2.070 (0.539-7.959)
0.290
Mitotic index, per 50 HPF
< 0.001
0.015
0-5
Reference
Reference
6-10
3.120 (0.913-10.669)
0.070
4.129 (0.963-17.707)
0.056
> 10
7.515 (3.045-18.548)
< 0.001
6.051 (1.762-20.778)
0.004
Surgical approach
0.684
Open
Reference
Laparoscopic
0.621 (0.213-1.815)
0.384
Endoscopic
0 (0-3.609E+275)
0.968
Blood transfusion
No
Reference
Reference
Yes
2.832 (1.312-6.113)
0.008
1.298 (0.547-3.082)
0.554
Intraoperative tumor rupture
No
Reference
Reference
Yes
5.094 (0.682-38.043)
0.113
3.264 (0.355-30.022)
0.296
Imatinib treatment
Yes
Reference
Reference
No
2.952 (1.113-7.831)
0.030
7.841 (2.677-22.693)
< 0.001
MGIST
Absent
Reference
Reference
Present
2.050 (0.889-4.726)
0.092
2.404 (0.830-6.966)
0.106
Citation: Wu H, Li C, Li H, Shang L, Jing HY, Liu J, Fang Z, Du FY, Liu Y, Fu MD, Jiang KW, Li LP. Clinicopathological characteristics and longterm survival of patients with synchronous multiple primary gastrointestinal stromal tumors: A propensity score matching analysis. World J Gastroenterol 2021; 27(36): 6128-6141